$25.96
1.07% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$25.96
+0.23 0.89% 1M
+2.10 8.80% 6M
+1.97 8.21% YTD
+3.77 16.99% 1Y
+5.26 25.41% 3Y
+7.97 44.26% 5Y
+24.37 1,532.70% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.28 1.07%
ISIN
US30161Q1040
Symbol
EXEL
Sector
Industry

Key metrics

Market capitalization $7.49b
Enterprise Value $6.68b
P/E (TTM) P/E ratio 22.47
EV/FCF (TTM) EV/FCF 24.07
EV/Sales (TTM) EV/Sales 3.32
P/S ratio (TTM) P/S ratio 3.72
P/B ratio (TTM) P/B ratio 3.53
Revenue growth (TTM) Revenue growth 17.48%
Revenue (TTM) Revenue $2.01b
EBIT (operating result TTM) EBIT $402.85m
Free Cash Flow (TTM) Free Cash Flow $277.54m
Cash position $1.00b
EPS (TTM) EPS $1.17
P/E forward 17.28
P/S forward 3.64
EV/Sales forward 3.25
Short interest 5.99%
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Exelixis, Inc. forecast:

15x Buy
65%
6x Hold
26%
2x Sell
9%

Analyst Opinions

23 Analysts have issued a Exelixis, Inc. forecast:

Buy
65%
Hold
26%
Sell
9%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2,014 2,014
17% 17%
100%
- Direct Costs 79 79
26% 26%
4%
1,935 1,935
17% 17%
96%
- Selling and Administrative Expenses 489 489
7% 7%
24%
- Research and Development Expense 1,016 1,016
1% 1%
50%
429 429
124% 124%
21%
- Depreciation and Amortization 27 27
47% 47%
1%
EBIT (Operating Income) EBIT 403 403
185% 185%
20%
Net Profit 350 350
113% 113%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Positive
The Motley Fool
one day ago
With e-commerce accounting for just 16% of U.S. retail sales, Shopify has plenty of runway ahead. Exelixis is an innovative drugmaker focusing on one of the most competitive areas in the industry.
Neutral
Business Wire
12 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (Tecentriq®) compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pe...
Neutral
Business Wire
about one month ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 9:15 a.m. ET / 6:15 a.m. PT on Wednesday, September 4 in New York City. 2024 Wells Fargo Healthcare Conference: E...
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,310
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today